Early Pregnancy Detection of Gestational Diabetes Mellitus Using Continuous Glucose Monitoring

What this Trial Is About

Gestational diabetes mellitus GDM is a common pregnancy complication affecting 10-15% of pregnancies and linked to short- and long-term health risks for both mother and baby. As maternal age and weight increase, so does the incidence of GDM, which is traditionally diagnosed later in pregnancy using an oral glucose tolerance test OGTT. Early detection could help manage risks like macrosomia, neonatal hypoglycemia, and maternal complications including hypertensive disorders and cesarean delivery. This observational study evaluates the use of continuous glucose monitoring CGM during the first trimester to predict GDM, comparing CGM results at 12 and 28 weeks of pregnancy with the standard OGTT at 28 weeks. Participants will wear a CGM device to track glucose levels continuously, aiming to identify early signs of GDM. No treatment interventions are applied, as the study focuses on monitoring and prediction in pregnant women. Participants will undergo CGM at 12 and 28 weeks of gestation, alongside routine OGTT testing at 28 weeks. Researchers will assess glucose profiles to evaluate CGMs predictive value for GDM. The study also tracks the occurrence of gestational hypertension. Participants will be monitored up to 28 weeks, with data collected on glucose patterns and pregnancy outcomes. The total participation period lasts until the 28th week of gestation.

First Trimester Prediction of Gestational Diabetes Mellitus by Continuous Glucose Monitoring.